Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy: Two-Year Results of the Aflibercept in Polypoidal Choroidal Vasculopathy Study

Wong, Tien Yin; Ogura, Yuichiro; Lee, Won Ki; Iida, Tomohiro; Chen, Shih‐Jen; Mitchell, Paul; Cheung, Chui Ming Gemmy; Zhang, Zhongqi; Leal, Sérgio; Ishibashi, Tatsuro; Investigators, Planet

doi:10.1016/j.ajo.2019.02.027

Cited by 78 publications

(100 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the current study, anti-VEGF monotherapy and combination therapy had comparable long-term visual outcomes, which was in accordance with the results of the PLANET study [4]. However, combination therapy in real world was considered for eyes with greater severity and activity according to current guidelines [2,10].…”

Section: Discussionsupporting

confidence: 85%

“…Currently, a wide spectrum of treatment options, including antivascular endothelial growth factor (anti-VEGF) therapy, photodynamic therapy (PDT), and various combinations of these therapies, have been performed in real world. Several clinical trials compared various treatment regimens [3][4][5][6][7].…”

Section: Introductionmentioning

confidence: 99%

“…e EVEREST-II study compared the intravitreal injection (IVT) of ranibizumab (IVT-R) and combination of PDT and IVT-R and concluded that combination therapy is preferred to IVR monotherapy [8]. Also, the PLANET study compared IVT aflibercept without and with rescue PDT after 3 months and suggested that no additional benefit was gained in combining with PDT as a rescue therapy [4].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Six-Year Real-World Outcomes of Antivascular Endothelial Growth Factor Monotherapy and Combination Therapy for Various Subtypes of Polypoidal Choroidal Vasculopathy

Yang

Yuan

Song

et al. 2019

Journal of Ophthalmology

View full text Add to dashboard Cite

The purpose of this study was to compare 6-year visual outcomes of antivascular endothelial growth factor (anti-VEGF) monotherapy and initial combination therapy of photodynamic therapy (PDT) and anti-VEGF therapy for polypoidal choroidal vasculopathy (PCV) in a Chinese population and to investigate imaging biomarkers associated with visual outcomes. Forty-eight treatment-naive PCV eyes of 46 patients were reviewed retrospectively, which underwent anti-VEGF monotherapy or initial combination therapy. PCV was classified into 2 subtypes. Mean best-corrected visual acuity (BCVA) using logarithm of minimal angle resolution and imaging morphological features was compared. No significant differences of mean BCVA changes were noticed between anti-VEGF monotherapy and combination therapy in either subtype 1 PCV or subtype 2 PCV during 6-year period (all P values >0.05). Compared with BCVA at baseline, the mean BCVA at 72 months deteriorated significantly in eyes with subtype 1 PCV (P<0.001), while the mean BCVA at 72 months remained stable in eyes with subtype 2 PCV (P=0.941). In subtype 2 PCV eyes with continuous retina pigment epithelium, the mean changes of BCVA in eyes treated with anti-VEGF monotherapy were better than those in eyes treated with combination therapy (P=0.020). Anti-VEGF monotherapy and combination therapy for various subtypes of PCV had comparable long-term visual outcomes in most cases in real world. Imaging biomarkers which correlate with visual outcomes and treatment response should be included in the classification of PCV and validated in real world.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Six-Year Real-World Outcomes of Antivascular Endothelial Growth Factor Monotherapy and Combination Therapy for Various Subtypes of Polypoidal Choroidal Vasculopathy

Yang

Yuan

Song

et al. 2019

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…В обеих группах пациенты получали интравитреальные инъекции афлиберцепта в дозе 2 мг каждые 2 мес. Начиная с 12-й недели исследования при соответствии критериям проведения «терапии спасения» пациенты в группе монотерапии афлиберцептом могли получать инъекции препарата каждый месяц и имитацию ФДТ, а в группе комбинированного лечения пациенты получали инъекции препарата каждый месяц и активную ФДТ [31,32]. Основные результаты за первый и второй годы терапии представлены в табл.…”

Section: особенности терапии полипоидной хориоидальной васкулопатииunclassified

“…Таким образом, монотерапия препаратом афлиберцепт продемонстрировала значительное Таблица 1 / Table 1 Среднее изменение функциональных и анатомических параметров в группах исследования PLANET за два года терапии Mean change in functional and anatomical parameters in different groups of PLANET study during 2 years of therapy Примечательно, что в подгруппах пациентов, которым потребовалась «терапия спасения», добавление ФДТ к анти-VEGF-терапии не дало дополнительных преимуществ относительно улучшения зрения. Так, в группе монотерапии афлиберцептом пациентов, которым была проведена «терапия спасения» с имитацией ФДТ, средняя прибавка остроты зрения составила 2,6 буквы по шкале ETDRS, в то время как в группе с активной ФДТ в качестве «терапии спасения» прибавки остроты зрения не отмечалось [32].…”

Section: особенности терапии полипоидной хориоидальной васкулопатииunclassified

Modern aspects of polypoidal choroidal vasculopathy diagnosis and treatment

Sokolov

Владимирович²,

Smirnov

et al. 2019

Ophthalmology Reports

View full text Add to dashboard Cite

Polypoidal choroidal vasculopathy (PCV) is one of the choroidal neovascularization forms, being a subtype of neovascular age-related macular degeneration (nAMD). These two conditions share many characteristics, while PCV has some distinctive features with aneurysmal dilatations (polyps) at the end of abnormal branching vascular network being the most specific of them. Low documented incidence of PCV in European population (up to 13%) may be related to the absence of indocyanin-green angiography (ICG) the only reliable method for PCV diagnosis confirmation in routine clinical practice. In that regard, there should be a universal method of treatment suitable for any patient with nAMD irrespectively of whether he or she has PCV. To date, there is no common approach to PCV treatment anti-VEGF therapy, photodynamic therapy (PDT), and combination of these methods are used in clinical practice. Key diagnostic criteria helping to suspect the presence of PCV without ICG as well as results of clinical trials aimed at assessing effectiveness of different anti-VEGF agents as monotherapy or in combination with PDT are described in this article.

show abstract

Cost-effectiveness of Intravitreal Ranibizumab With Verteporfin Photodynamic Therapy Compared With Ranibizumab Monotherapy for Patients With Polypoidal Choroidal Vasculopathy

et al. 2020

Self Cite

View full text Add to dashboard Cite

trial showed that for patients with polypoidal choroidal vasculopathy (PCV), intravitreal ranibizumab in combination with verteporfin photodynamic therapy improves visual acuity relative to ranibizumab monotherapy. However, whether combination therapy is incrementally cost-effective relative to monotherapy during a lifetime is unclear.OBJECTIVE To assess the incremental cost-effectiveness of combination therapy compared with ranibizumab monotherapy in patients with PCV. DESIGN, SETTING, AND PARTICIPANTSThis model-based, economic evaluation used 2018 unit cost data from a tertiary eye hospital in Singapore, first-and second-year outcomes and resource use data from a multicenter trial across various Asian countries (EVEREST II) to model a hypothetical cohort of patients with symptomatic PCV. Scenario analyses and deterministic and probabilistic sensitivity analyses were performed to examine uncertainty.

show abstract

Efficacy and Safety of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy: Two-Year Results of the Aflibercept in Polypoidal Choroidal Vasculopathy Study

Cited by 78 publications

References 37 publications

Six-Year Real-World Outcomes of Antivascular Endothelial Growth Factor Monotherapy and Combination Therapy for Various Subtypes of Polypoidal Choroidal Vasculopathy

Six-Year Real-World Outcomes of Antivascular Endothelial Growth Factor Monotherapy and Combination Therapy for Various Subtypes of Polypoidal Choroidal Vasculopathy

Modern aspects of polypoidal choroidal vasculopathy diagnosis and treatment

Cost-effectiveness of Intravitreal Ranibizumab With Verteporfin Photodynamic Therapy Compared With Ranibizumab Monotherapy for Patients With Polypoidal Choroidal Vasculopathy

Contact Info

Product

Resources

About